News | June 25, 2024
Sun Pharma completes Taro merger
Combined entity is better positioned to compete in increasingly competitive generics industry
Combined entity is better positioned to compete in increasingly competitive generics industry
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Alchemee's flagship brand Proactiv@ is an iconic product synonymous with acne care
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Nystatin and Triamcinolone Acetonide ointment is indicated for the treatment of cutaneous candidiasis
Subscribe To Our Newsletter & Stay Updated
